Abstracts tagged "Sjogren’s syndrome and clinical trials"

Abstract Number: 3203 • 2015 ACR/ARHP Annual Meeting
The Clinical Efficacy and Safety of Baminercept, a Lymphotoxin-Beta Receptor Fusion Protein, in Primary Sjögren’s Syndrome: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Trial
E. William St.Clair¹, Alan N. Baer², Ghaith Noaiseh³, Anne Parke⁴, Andreea Coca⁵, Tammy Utset⁶, Mark C. Genovese⁷, Daniel J Wallace⁸, James McNamara⁹, Karen Boyle¹⁰, Lynette Keyes-Elstein¹⁰, Nathalie Franchimont¹¹, Judith A James¹² and for the Autoimmunity Centers of Excellence supported by a grant from NIAID 5U19-AI056363, ¹Medicine, Duke University, Durham, NC, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³University of Pittsburgh Medical Center, Pittsburgh, PA, ⁴University of Connecticut, Farmington, CT, ⁵University of Rochester Medical Center, Rochester, NY, ⁶University of Chicago, Chicago, IL, ⁷Division of Rheumatology, Stanford University Medical Center, Palo Alto, CA, ⁸Cedars-Sinai Medical Center, West Hollywood, CA, ⁹NIAID/NIH, Bethesda, MD, ¹⁰Rho Federal Systems, Inc., Chapel Hill, NC, ¹¹Biogen, Cambridge, MA, ¹²OMRF, OU, Oklahoma City, OK
Background/Purpose: Primary Sjögren’s syndrome (pSjS) is characterized by chronic inflammation of the lacrimal and salivary glands, as well as frequent extraglandular involvement and increased risk…
Abstract Number: 2188 • 2012 ACR/ARHP Annual Meeting
How to Better Define Inclusion Criteria in a Large Controlled Trial in Primary Sjogren Syndrome ?
Valerie Devauchelle-Pensec¹, Xavier Mariette², Jacques-Eric Gottenberg³, Raphaèle Seror⁴, Anne-Laure Fauchais⁵, Olivier Vittecoq⁶, Véronique Le Guern⁷, Jacques Morel⁸, JJ Dubost⁹, Philippe Dieude¹⁰, Eric Hachulla¹¹, Pierre yves Hatron¹², C. Larroche¹³, Aleth Perdriger¹⁴, Xavier Puechal¹⁵, Damien Sene Sr.¹⁶, Stephanie Rist¹⁷ and Alain Saraux¹⁸, ¹Department of rheumatology and unit of immunology EA2216, Brest Occidentale university, Brest, France, ²Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France, ³Rheumatology, Strasbourg University Hospital, Strasbourg, France, ⁴Rheumatology, Bicetre university hospital, LE Kremlin-Bicetre, France, ⁵Department of Internal Medicine A, Dupuytren Hospital, Limoges University Hospital, Limoges, France, ⁶Rheumatology, Rouen University Hospital & Inserm905, University of Rouen, Rouen Cedex, France, ⁷Department of Internal Medicine, Cochin Hospital, Paris, France, ⁸Dpartment of Rheumatology, Lapeyronie Hospital, Montpellier, France, ⁹Rheumatology, CHU CLERMONT-FERRAND, Clermont-Ferrand, France, ¹⁰Rheumatology, Rheumatology departement & INSERM U699, Paris Diderot university, APHP, Bichat hospital, Paris, France, ¹¹Department of Internal Medicine, Claude Huriez University Hospital, Lille, France, ¹²Department of Internal Medicine, Hôpital Claude Huriez, Université Lille II, Lille, France, Paris, France, ¹³Hospital University Bobigny, bobigny, France, ¹⁴Rheumatology, Hôpital Sud, Rennes, France, ¹⁵Internal Medicine, Hôpital Cochin, Paris, France, ¹⁶Department of Internal Medicine; 5 P3S post-genomic plateform, Groupe Hospitalier Pitié-Salpétrière, Université Pierre et Marie Curie, Paris, France, ¹⁷Rheumatology, Orleans Hospital, Orleans, France, ¹⁸Department of rheumatology and unit of immunology (EA 2216), Université Brest Occidentale, Brest, France
Background/Purpose: The subsets of primary Sjögren's syndrome (pSS) patients justifying biological therapy (BT) remain a matter of debate. Our goal was [1] to describe which…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].